Time spent at blood pressure target and the risk of death and cardiovascular diseases

Sheng-Chia Chung, Mar Pujades-Rodriguez, Bram Duyx, Spiros C Denaxas, Laura Pasea, Aroon Hingorani, Adam Timmis, Bryan Williams, Harry Hemingway, Sheng-Chia Chung, Mar Pujades-Rodriguez, Bram Duyx, Spiros C Denaxas, Laura Pasea, Aroon Hingorani, Adam Timmis, Bryan Williams, Harry Hemingway

Abstract

Background: The time a patient spends with blood pressure at target level is an intuitive measure of successful BP management, but population studies on its effectiveness are as yet unavailable.

Method: We identified a population-based cohort of 169,082 individuals with newly identified high blood pressure who were free of cardiovascular disease from January 1997 to March 2010. We used 1.64 million clinical blood pressure readings to calculate the TIme at TaRgEt (TITRE) based on current target blood pressure levels.

Result: The median (Inter-quartile range) TITRE among all patients was 2.8 (0.3, 5.6) months per year, only 1077 (0.6%) patients had a TITRE ≥11 months. Compared to people with a 0% TITRE, patients with a TITRE of 3-5.9 months, and 6-8.9 months had 75% and 78% lower odds of the composite of cardiovascular death, myocardial infarction and stroke (adjusted odds ratios, 0.25 (95% confidence interval: 0.21, 0.31) and 0.22 (0.17, 0.27), respectively). These associations were consistent for heart failure and any cardiovascular disease and death (comparing a 3-5.9 month to 0% TITRE, 63% and 60% lower in odds, respectively), among people who did or did not have blood pressure 'controlled' on a single occasion during the first year of follow-up, and across groups defined by number of follow-up BP measure categories.

Conclusion: Based on the current frequency of measurement of blood pressure this study suggests that few newly hypertensive patients sustained a complete, year-round on target blood pressure over time. The inverse associations between a higher TITRE and lower risk of incident cardiovascular diseases were independent of widely-used blood pressure 'control' indicators. Randomized trials are required to evaluate interventions to increase a person's time spent at blood pressure target.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Definition of newly identified hypertension,…
Fig 1. Definition of newly identified hypertension, average annual time at target (TITRE) and fatal and non-fatal cardiovascular events.
1 BP <140/90 mmHg, or <150/90 for patients aged 60 years or more without diabetes and chronic kidney disease. BP: blood pressure. CVD: cardiovascular disease. 2 For each patient, the days that blood pressure was at target between two consecutive measures were summed to calculate the percent time at target for each follow-up year, and then averaged over follow-up years. Details are described in S1 Method. 3 Incident cardiovascular disease include: myocardial infarction, stroke (including ischemic stroke, intracerebral hemorrhage and sub-arachnoid hemorrhage), heart failure, angina, atrial fibrillation, transient ischemic attack, peripheral artery disease, abdominal aortic aneurysm and cardiovascular and non-cardiovascular mortality.) It is unclear to what the (1) refers to in the figure.
Fig 2. Time at target (TITRE) distribution…
Fig 2. Time at target (TITRE) distribution in patients with recorded TITRE (N = 150130).
*Median 2.8 (0.3, 5.6) months.
Fig 3. Patient characteristics and their association…
Fig 3. Patient characteristics and their association with a higher or lower TITRE (%).
Fig 4. Associations between categorical time at…
Fig 4. Associations between categorical time at target (TITRE) and primary (composite of cardiovascular mortality, myocardial infarction and stroke, incident heart failure and any cardiovascular diseases) and secondary (stable angina, peripheral artery disease, and all-cause mortality) study endpoints (n = 169082).

References

    1. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. (2014) Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 383: 1899–1911. 10.1016/S0140-6736(14)60685-1
    1. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34: 2159–2219. 10.1093/eurheartj/eht151
    1. Law MR, Morris JK, Wald NJ (2009) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338: b1665 10.1136/bmj.b1665
    1. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018. May 15;71(19):e127–e248. 10.1016/j.jacc.2017.11.006
    1. Blood Pressure Lowering Treatment Trialists C, Sundstrom J, Arima H, Woodward M, Jackson R, Karmali K, et al. (2014) Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 384: 591–598. 10.1016/S0140-6736(14)61212-5
    1. NICE (2011) Hypertension: The clinical management of primary hypertension in adults NICE clinical guideline 127 [NICE guideline].
    1. Egan BM, Zhao Y, Axon RN (2010) US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA 303: 2043–2050. 10.1001/jama.2010.650
    1. Falaschetti E, Mindell J, Knott C, Poulter N (2014) Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet 383: 1912–1919. 10.1016/S0140-6736(14)60688-7
    1. Giannattasio C, Cairo M, Cesana F, Alloni M, Sormani P, Colombo G, et al. (2012) Blood pressure control in Italian essential hypertensives treated by general practitioners. Am J Hypertens 25: 1182–1187. 10.1038/ajh.2012.108
    1. Tocci G, Nati G, Cricelli C, Parretti D, Lapi F, Ferrucci A, et al. (2017) Prevalence and control of hypertension in the general practice in Italy: updated analysis of a large database. J Hum Hypertens 31: 258–262. 10.1038/jhh.2016.71
    1. Brook RD, Rajagopalan S (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American Society of Hypertension 12: 238–238. 10.1016/j.jash.2018.01.004
    1. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358: 1887–1898. 10.1056/NEJMoa0801369
    1. Group SR, Wright JT Jr., Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. (2015) A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 373: 2103–2116. 10.1056/NEJMoa1511939
    1. Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, et al. (2009) Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 374: 525–533. 10.1016/S0140-6736(09)61340-4
    1. Kengne AP, Czernichow S, Huxley R, Grobbee D, Woodward M, Neal B, et al. (2009) Blood pressure variables and cardiovascular risk: new findings from ADVANCE. Hypertension 54: 399–404. 10.1161/HYPERTENSIONAHA.109.133041
    1. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. (2013) A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 369: 2294–2303. 10.1056/NEJMoa1311386
    1. Rothwell PM (2010) Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 375: 938–948. 10.1016/S0140-6736(10)60309-1
    1. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlof B, et al. (2010) Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 375: 895–905. 10.1016/S0140-6736(10)60308-X
    1. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. (2016) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387: 957–967. 10.1016/S0140-6736(15)01225-8
    1. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. (2015) Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet.
    1. Quality and Outcomes Framework Indicators, the national institute for health and clinical excellence (NICE).
    1. Denaxas SC, George J, Herrett E, Shah AD, Kalra D, Hingorani AD, et al. (2012) Data resource profile: cardiovascular disease research using linked bespoke studies and electronic health records (CALIBER). Int J Epidemiol 41: 1625–1638. 10.1093/ije/dys188
    1. George J, Rapsomaniki E, Pujades-Rodriguez M, Shah AD, Denaxas S, Herrett E, et al. (2015) How Does Cardiovascular Disease First Present in Women and Men? Incidence of 12 Cardiovascular Diseases in a Contemporary Cohort of 1,937,360 People. Circulation 132: 1320–1328. 10.1161/CIRCULATIONAHA.114.013797
    1. Koudstaal S P-RM, Denaxas S, Gho JMIH, Shah AD, Gale CP, Hoes AW, Cleland JG, Asselbergs FW, Hemingway H (2016) Prognostic burden of heart failure diagnosed in primary care or secondary care: a population-based linked electronic health record cohort study in 2.1 million people. European Journal of Heart Failure 18: 161–162.
    1. Morley KI, Wallace J, Denaxas SC, Hunter RJ, Patel RS, Perel P, et al. (2014) Defining disease phenotypes using national linked electronic health records: a case study of atrial fibrillation. PLoS One 9: e110900 10.1371/journal.pone.0110900
    1. Herrett E, Shah AD, Boggon R, Denaxas S, Smeeth L, van Staa T, et al. (2013) Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study. BMJ 346: f2350 10.1136/bmj.f2350
    1. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, et al. (2015) Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol 3: 105–113. 10.1016/S2213-8587(14)70219-0
    1. A’Court C, Stevens R, Sanders S, Ward A, McManus R, Heneghan C (2011) Type and accuracy of sphygmomanometers in primary care: a cross-sectional observational study. Br J Gen Pract 61: e598–603. 10.3399/bjgp11X593884
    1. National Institute for Clinical Excellence. Essential hypertension: managing adult patients in primary care: partial update London: National Institute for Clinical Excellence; 2006.
    1. (2004) National Institute for Clinical Excellence. Clinical Guideline 18 Hypertension—management of hypertension in adults in primary care.
    1. Ramsay L, Williams B, Johnston G, MacGregor G, Poston L, Potter J, et al. (1999) Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 13: 569–592.
    1. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69: 236–239.
    1. Pujades-Rodriguez M, Timmis A, Stogiannis D, Rapsomaniki E, Denaxas S, Shah A, et al. (2014) Socioeconomic deprivation and the incidence of 12 cardiovascular diseases in 1.9 million women and men: implications for risk prediction and prevention. PLoS One 9: e104671 10.1371/journal.pone.0104671
    1. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247–254.
    1. Hyman DJ, Pavlik VN (2001) Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 345: 479–486. 10.1056/NEJMoa010273
    1. Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. (2013) Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 34: 2940–2948. 10.1093/eurheartj/eht295
    1. Group AS, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, et al. (2007) Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 99: 21i–33i. 10.1016/j.amjcard.2007.03.003
    1. Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM, et al. (2004) Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 363: 1925–1933. 10.1016/S0140-6736(04)16405-2
    1. Hippisley-Cox J, Coupland C, Brindle P (2017) Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 357: j2099 10.1136/bmj.j2099
    1. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. (2013) Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 310: 959–968. 10.1001/jama.2013.184182
    1. Sharma AM, Wittchen HU, Kirch W, Pittrow D, Ritz E, Goke B, et al. (2004) High prevalence and poor control of hypertension in primary care: cross-sectional study. Journal of Hypertension 22: 479–486.
    1. Xu W, Goldberg SI, Shubina M, Turchin A (2015) Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study. BMJ 350: h158 10.1136/bmj.h158
    1. Margolis KL, Asche SE, Bergdall AR, Dehmer SP, Groen SE, Kadrmas HM, et al. (2013) Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA 310: 46–56. 10.1001/jama.2013.6549
    1. McManus RJ, Mant J, Bray EP, Holder R, Jones MI, Greenfield S, et al. (2010) Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet 376: 163–172. 10.1016/S0140-6736(10)60964-6

Source: PubMed

3
구독하다